Phaseline

Targets › ANGPTL3

ANGPTL3 (Angiopoietin-related protein 3): drug programs, companies and trials

6 programs from 6 companies in 8 trials: 3 Phase 3, 3 Phase 1, 2 Phase 2; Metabolic and endocrine; next expected readout Dec 2026.

Acts in part as a hepatokine that is involved in regulation of lipid and glucose metabolism. Proposed to play a role in the trafficking of energy substrates to either storage or oxidative tissues in response to food intake (By similarity). (UniProt, Q9Y5C1)

Open in Phaseline: the race on ANGPTL3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Arrowhead PharmaceuticalsZodasiran
ANGPTL3 antisense oligonucleotide
ANGPTL3Phase 3Homozygous Familial HypercholesterolemiaAug 2027
Visirna Therapeutics HKVSA003
RNA interference (RNAi) therapeutic targeting ANGPTL3
ANGPTL3Phase 3Homozygous Familial Hypercholesterolemia (HoFH)Dec 2027
Regeneron PharmaceuticalsALN-ANG3
ANGPTL3 inhibitor
ANGPTL3Phase 2Diabetic Kidney Disease (DKD); Healthy Volunteers With HyperlipidemiaDec 2026
Eddingpharm (Zhuhai)EDP167
siRNA targeting ANGPTL3
ANGPTL3Phase 2Homozygous Familial Hypercholesterolemia (HoFH)Mar 2027
CRISPR TherapeuticsCTX310
In vivo CRISPR-Cas9 gene editing targeting ANGPTL3
ANGPTL3Phase 1CardiovascularJun 2027
Verve TherapeuticsVERVE-201
Base-editing technology to inactivate ANGPTL3 gene expression in hepatocytes
ANGPTL3Phase 1HypercholesterolemiaDec 2027

Conditions

Homozygous Familial Hypercholesterolemia (HoFH) (2) Homozygous Familial Hypercholesterolemia (2) Diabetic Kidney Disease (DKD) (1) Healthy Volunteers With Hyperlipidemia (1) Hypercholesterolemia (1) Cardiovascular (1)

Modalities

small molecule (3), other (2), mixed (1)

Companies

Visirna Therapeutics HK (1) Regeneron Pharmaceuticals (1) Eddingpharm (Zhuhai) (1) Verve Therapeutics (1) Arrowhead Pharmaceuticals (1) CRISPR Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.